# Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable P

Source: https://onco.cc/trials/nct07436741/  
OnCo record `nct07436741` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of gemcitabine + nab-paclitaxel in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.

## Summary

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT07436741 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 106 participants, started 2026-03-03 and due to reach its primary completion in 2028-09. Interventions recorded: surufatinib + gemcitabine + nab-paclitaxel; gemcitabine + nab-paclitaxel. Conditions listed: Pancreatic Cancer, Adult. Primary outcome: Surgical complete resection rate (R0). Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed high-risk resectable or borderline resectable pancreatic cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07436741
- Phase: 3
- Setting: A Prospective, Randomized, Controlled, Multi-center Clinical Trial of Surufatinib Combined With Gemcitabine and Nab-paclitaxel Versus Gemcitabine Combined With Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 106

## Sources

- ClinicalTrials.gov NCT07436741: https://clinicaltrials.gov/study/NCT07436741

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07436741.json